Oncology : Horizon 2030
Technologies and models to address tumor heterogeneity for better personalized medicine
Eurobiomed Cluster invites you to its next thematic meeting dedicated to oncology, in partnership with the Occitanie Region, Ad’occ and Toulouse Métropole. This day will address the prospects in oncology by 2030. More specifically, it will focus on innovations in precision medicine and heterogeneity of tumors, themes opening up prospects for more personalized medicine for better patient care.
Program
8:45 : Welcome
9:15 : Opening
- Michael DANON – President of Eurobiomed
- Vincent BOUNES, Vice President of Occitanie Region in charge of health
- Patricia BEZ, Deputy Major of Toulouse Metropole in charge of Health
9:40 : Glioblastoma : an example of tumor heterogeneity and a major medical challenge
Pr Elizabeth MOYAL – Neuro-oncologist and Head of the radiotherapy department – Institut Universitaire du Cancer – Toulouse Oncopole
10:05 : Current scientific and industrial approaches to address tumor heterogeneity and microenvironment – 1st session
- Multimodal single cell omics : a technological revolution for fundamental and clinical oncology
Jean-Jacques FOURNIE, Centre de Recherche en Cancérologie de Toulouse - Computational biology approaches to characterise and model the tumour microenvironment
Vera PANCALDI, Centre de Recherche en Cancérologie de Toulouse - Development of NIK modulators for cancer treatment
Arnaud FOUSSAT, CEO Yukin Therapeutics
11:15 : Coffee Break
11:35 : Current scientific and industrial approaches to address tumor heterogeneity and microenvironment – 2nd session
- Role of stromal heterogeneity in immunosuppression and resistance to immunotherapy in cancer
Fatima MECHTA-GRIGORIOU, Institut Curie (by videoconference) - Harnessing innate immunity in cancer therapy
Ariane MOREL, Director R&D – Pharmacology Department, Innate Pharma
12:20 : High-plex tissue imaging: an integrative way to analyze tumor microenvironment contexture and spatial heterogeneity
Aïda MEGHRAOUI-KHEDDAR, CEO AMKbiotech
12:25 : Lunch
14:00 : Current scientific and industrial approaches to address tumor heterogeneity and microenvironment – 3rd session
- Protein glycosylation and cellular interfaces in cancer biology
Frédéric BARD, Centre de Recherche en Cancérologie de Marseille - What is neutrophil homeostasis telling us on immune checkpoint blockade in NSCLC?
Julien FAGET, Institut de Recherche en Cancérologie de Montpellier - High endothelial venules (HEVs): specialized blood vessels for lymphocyte entry into tumors during cancer immunotherapy
Jean-Philippe GIRARD, Institut de Pharmacologie et de Biologie Structurale de Toulouse - Diag2tec’s tools and models to study the response to new therapeutic agents in hematological malignancies
Djamila CHEMLAL , PhD Student Diag2tec - Microbiomes contribute to tumor microenvironment, progression and treatment responsiveness
Céline RIBIERE, Microbiome Scientist Vaiomer
15:55 : Oncology at Pierre Fabre – A strategic perspective
Francesco HOFMANN Medical Care R&D Director
16:20 : Closing by Eurobiomed
16:25 : End of the event
Information : Leïla TOUIHRI
Event sponsored by
With the support of the scientific committee
